Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity
Authors
Keywords
-
Journal
Scientific Reports
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-10-27
DOI
10.1038/s41598-022-22975-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Anticancer bispecific antibody R&D advances: a study focusing on research trend worldwide and in China
- (2021) Zhonghan Zhang et al. Journal of Hematology & Oncology
- Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development
- (2021) Anand Rotte et al. Biomedicines
- Positive charge in the complementarity-determining regions of synthetic nanobody prevents aggregation
- (2021) Zhenwei Zhong et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies
- (2020) Brian H. Santich et al. Science Translational Medicine
- A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade
- (2020) Linlin Ma et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects
- (2020) Fang Yang et al. JOURNAL OF IMMUNOLOGY
- PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade
- (2020) Qi Peng et al. Nature Communications
- Nanobody approval gives domain antibodies a boost
- (2019) Chris Morrison NATURE REVIEWS DRUG DISCOVERY
- Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens
- (2018) Jeremy D. Waight et al. CANCER CELL
- Therapeutic bispecific antibody formats: a patent applications review (1994-2017)
- (2018) Marie Godar et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
- (2018) Qing Zhang et al. NATURE IMMUNOLOGY
- Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated Counterparts
- (2018) Christoph Goletz et al. Frontiers in Immunology
- Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity
- (2018) Takehisa Kitazawa et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)
- (2018) Marcin Kowanetz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The making of bispecific antibodies
- (2017) Ulrich Brinkmann et al. mAbs
- Enhancing Stability of Camelid and Shark Single Domain Antibodies: An Overview
- (2017) Ellen R. Goldman et al. Frontiers in Immunology
- Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody
- (2017) Renee N. Donahue et al. Journal for ImmunoTherapy of Cancer
- A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor–Resistant Lung Tumors
- (2016) Sheri L. Moores et al. CANCER RESEARCH
- Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications
- (2016) Min Zhu et al. CLINICAL PHARMACOKINETICS
- FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis
- (2015) Rony Dahan et al. CANCER CELL
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Adaptive Immune Resistance: How Cancer Protects from Immune Attack
- (2015) A. Ribas Cancer Discovery
- The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
- (2014) Robert J. Johnston et al. CANCER CELL
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Negative tail fusions can improve ruggedness of single domain antibodies
- (2014) Ellen R. Goldman et al. PROTEIN EXPRESSION AND PURIFICATION
- Discovery and Investigation of O-Xylosylation in Engineered Proteins Containing a (GGGGS)n Linker
- (2013) Dingyi Wen et al. ANALYTICAL CHEMISTRY
- Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR
- (2013) Noa Stanietsky et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Fusion protein linkers: Property, design and functionality
- (2012) Xiaoying Chen et al. ADVANCED DRUG DELIVERY REVIEWS
- Development of tetravalent IgG1 dual targeting IGF-1R–EGFR antibodies with potent tumor inhibition
- (2012) Rebecca Croasdale et al. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- Development of Tetravalent, Bispecific CCR5 Antibodies with Antiviral Activity against CCR5 Monoclonal Antibody-Resistant HIV-1 Strains
- (2011) Jürgen Schanzer et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Catumaxomab
- (2010) Rolf Linke et al. mAbs
- Thermodynamically Stable Aggregation-Resistant Antibody Domains through Directed Evolution
- (2008) Kristoffer Famm et al. JOURNAL OF MOLECULAR BIOLOGY
- Aggregation-resistant VHs selected by in vitro evolution tend to have disulfide-bonded loops and acidic isoelectric points
- (2008) M. Arbabi-Ghahroudi et al. PROTEIN ENGINEERING DESIGN & SELECTION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now